Modified epitopes for boosting CD4+ T-cell responses
US10899795B2 · kind B2 · utility
Assignees
Inventor
Key dates
| Filing date | Jan 30, 2013 |
| Grant date | Jan 26, 2021 |
| Priority date | — |
| Expiry date | Oct 26, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.